In this video, Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the important role of CD47 as a target in myeloid malignancies, highlighting agents such as magrolimab and evorpacept. Dr Erba outlines preliminary data from the Phase Ia dose escalation part of the ASPEN-05 study (NCT04755244), which is evaluating the safety and tolerability of evorpacept administered in combination with standard venetoclax and azacitidine in patients with acute myeloid leukemia (AML). Preliminary results have shown that the addition of evorpacept to standard dose venetoclax and azacitidine is well tolerated, with some patients already demonstrating peripheral blood blast clearance. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.